PuSH - Publikationsserver des Helmholtz Zentrums München

Toporkiewicz, M.* ; Meissner, J.* ; Matusewicz, L.* ; Czogalla, A.* ; Sikorski, A.F.*

Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: Principles, hopes, and challenges.

Int. J. Nanomed. 10, 1399-1414 (2015)
DOI Verlagsversion bestellen
Open Access Gold möglich sobald Verlagsversion bei der ZB eingereicht worden ist.
There are many problems directly correlated with the systemic administration of drugs and how they reach their target site. Targeting promises to be a hopeful strategy as an improved means of drug delivery, with reduced toxicity and minimal adverse side effects. Targeting exploits the high affinity of cell-surface-targeted ligands, either directly or as carriers for a drug, for specific retention and uptake by the targeted diseased cells. One of the most important parameters which should be taken into consideration in the selection of an appropriate ligand for targeting is the binding affinity (K D). In this review we focus on the importance of binding affinities of monoclonal antibodies, antibody derivatives, peptides, aptamers, DARPins, and small targeting molecules in the process of selection of the most suitable ligand for targeting of nanoparticles. In order to provide a critical comparison between these various options, we have also assessed each technology format across a range of parameters such as molecular size, immunogenicity, costs of production, clinical profiles, and examples of the level of selectivity and toxicity of each. Wherever possible, we have also assessed how incorporating such a targeted approach compares with, or is superior to, original treatments.
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Egfr ; Cancer ; Drug Delivery ; Monoclonal Antibody ; Targeting ; Tumor
ISSN (print) / ISBN 1176-9114
e-ISSN 1178-2013
Quellenangaben Band: 10, Heft: , Seiten: 1399-1414 Artikelnummer: , Supplement: ,
Verlag Dove Medical Press
Verlagsort Albany, Auckland
Begutachtungsstatus Peer reviewed
Institut(e) Institute for Pancreatic Beta Cell Research (IPI)